These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 35994200)

  • 61. Efficacy and safety of golimumab 52-week maintenance therapy in Japanese patients with moderate to severely active ulcerative colitis: a phase 3, double-blind, randomized, placebo-controlled study-(PURSUIT-J study).
    Hibi T; Imai Y; Senoo A; Ohta K; Ukyo Y
    J Gastroenterol; 2017 Oct; 52(10):1101-1111. PubMed ID: 28324167
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Type I interferons for induction of remission in ulcerative colitis.
    Wang Y; MacDonald JK; Benchimol EI; Griffiths AM; Steinhart AH; Panaccione R; Seow CH
    Cochrane Database Syst Rev; 2015 Sep; 2015(9):CD006790. PubMed ID: 26368001
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Ozanimod in relapsing multiple sclerosis: Pooled safety results from the clinical development program.
    Selmaj KW; Cohen JA; Comi G; Bar-Or A; Arnold DL; Steinman L; Hartung HP; Montalban X; Havrdova EK; Cree BAC; Minton N; Sheffield JK; Ding N; Kappos L
    Mult Scler Relat Disord; 2021 Jun; 51():102844. PubMed ID: 33892317
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Unfractionated or low-molecular weight heparin for induction of remission in ulcerative colitis.
    Chande N; McDonald JW; Macdonald JK
    Cochrane Database Syst Rev; 2008 Apr; (2):CD006774. PubMed ID: 18425969
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Efficacy of Fecal Microbiota Transplantation in the Treatment of Active Ulcerative Colitis: A Systematic Review and Meta-Analysis of Double-Blind Randomized Controlled Trials.
    El Hage Chehade N; Ghoneim S; Shah S; Chahine A; Mourad FH; Francis FF; Binion DG; Farraye FA; Hashash JG
    Inflamm Bowel Dis; 2023 May; 29(5):808-817. PubMed ID: 35766805
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial.
    Cohen JA; Arnold DL; Comi G; Bar-Or A; Gujrathi S; Hartung JP; Cravets M; Olson A; Frohna PA; Selmaj KW;
    Lancet Neurol; 2016 Apr; 15(4):373-81. PubMed ID: 26879276
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Results From the First-in-Human Study With Ozanimod, a Novel, Selective Sphingosine-1-Phosphate Receptor Modulator.
    Tran JQ; Hartung JP; Peach RJ; Boehm MF; Rosen H; Smith H; Brooks JL; Timony GA; Olson AD; Gujrathi S; Frohna PA
    J Clin Pharmacol; 2017 Aug; 57(8):988-996. PubMed ID: 28398597
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial.
    Cree BA; Selmaj KW; Steinman L; Comi G; Bar-Or A; Arnold DL; Hartung HP; Montalbán X; Havrdová EK; Sheffield JK; Minton N; Cheng CY; Silva D; Kappos L; Cohen JA
    Mult Scler; 2022 Oct; 28(12):1944-1962. PubMed ID: 35765217
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Ozanimod for the treatment of relapsing forms of multiple sclerosis.
    Kuczynski AM; Oh J
    Neurodegener Dis Manag; 2021 Jun; 11(3):207-220. PubMed ID: 34011158
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Lyophilised oral faecal microbiota transplantation for ulcerative colitis (LOTUS): a randomised, double-blind, placebo-controlled trial.
    Haifer C; Paramsothy S; Kaakoush NO; Saikal A; Ghaly S; Yang T; Luu LDW; Borody TJ; Leong RW
    Lancet Gastroenterol Hepatol; 2022 Feb; 7(2):141-151. PubMed ID: 34863330
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Four-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative colitis: Data from ULTRA 1, 2, and 3.
    Colombel JF; Sandborn WJ; Ghosh S; Wolf DC; Panaccione R; Feagan B; Reinisch W; Robinson AM; Lazar A; Kron M; Huang B; Skup M; Thakkar RB
    Am J Gastroenterol; 2014 Nov; 109(11):1771-80. PubMed ID: 25155227
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Probiotics for maintenance of remission in ulcerative colitis.
    Iheozor-Ejiofor Z; Kaur L; Gordon M; Baines PA; Sinopoulou V; Akobeng AK
    Cochrane Database Syst Rev; 2020 Mar; 3(3):CD007443. PubMed ID: 32128794
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Tacrolimus (FK506) for induction of remission in corticosteroid-refractory ulcerative colitis.
    Gordon M; Sinopoulou V; Akobeng AK; Pana M; Gasiea R; Moran GW
    Cochrane Database Syst Rev; 2022 Apr; 4(4):CD007216. PubMed ID: 35388476
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Etrasimod for the treatment of ulcerative colitis.
    Wils P; Peyrin-Biroulet L
    Immunotherapy; 2023 Apr; 15(5):311-321. PubMed ID: 36789612
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial.
    Hanauer SB; Sandborn WJ; Kornbluth A; Katz S; Safdi M; Woogen S; Regalli G; Yeh C; Smith-Hall N; Ajayi F
    Am J Gastroenterol; 2005 Nov; 100(11):2478-85. PubMed ID: 16279903
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Transdermal nicotine for induction of remission in ulcerative colitis.
    McGrath J; McDonald JW; Macdonald JK
    Cochrane Database Syst Rev; 2004 Oct; (4):CD004722. PubMed ID: 15495126
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis.
    Sandborn WJ; Baert F; Danese S; Krznarić Ž; Kobayashi T; Yao X; Chen J; Rosario M; Bhatia S; Kisfalvi K; D'Haens G; Vermeire S
    Gastroenterology; 2020 Feb; 158(3):562-572.e12. PubMed ID: 31470005
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Ameliorating Active Ulcerative Colitis via an Orally Available Toll-Like Receptor-9 Modifier: A Prospective Open-Label, Multicenter Phase II Trial.
    Dotan I; Levy-Nissenbaum E; Chowers Y; Fich A; Israeli E; Adar T; Shteingart S; Soreq H; Goldin E
    Dig Dis Sci; 2016 Nov; 61(11):3246-3254. PubMed ID: 27572942
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Oral delayed-release mesalazine: a review of its use in ulcerative colitis and Crohn's disease.
    Prakash A; Markham A
    Drugs; 1999 Mar; 57(3):383-408. PubMed ID: 10193690
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Efficacy and Safety of Adalimumab in Moderately to Severely Active Cases of Ulcerative Colitis: A Meta-Analysis of Published Placebo-Controlled Trials.
    Zhang ZM; Li W; Jiang XL
    Gut Liver; 2016 Mar; 10(2):262-74. PubMed ID: 26780088
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.